CPMV Mosaic ImmunoEngineering Inc.

CIK 0000836564 7 ready 8-Ks latest January 2, 2025, 6:59 PM ET RSS · JSON

Ready 8-Ks 7

Latest filing January 2, 2025, 6:59 PM ET

Top materiality 0.85

Event mix leadership ×3 · m_and_a ×2 · other_material ×2

Sentiment 1 pos · 3 neg · 3 neu

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for CPMV

Highest-materiality recent filing

CWRU terminates Mosaic's CPMV license for lead candidate MIE-101 over ~$407K unpaid IP fees

March 28, 2024, 7:59 PM ET other material materiality 0.85 negative item 1.01 item 1.02 ◈ Material Agreements

Effective March 22, 2024, CWRU terminated the exclusive worldwide license agreement due to financial default.
Amount owed to CWRU increased to approximately $407,000 as of Dec. 31, 2023; company lacks capital to pay.

Read filing →

January 2, 2025, 6:59 PM ET M&A materiality 0.40 neutral item 8.01 item 9.01

Mosaic ImmunoEngineering extends Oncotelic acquisition term sheet to June 30, 2025

Binding term sheet for acquisition of Oncotelic's necroptosis cancer therapies and AI tech extended to June 30, 2025.
July 25, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Director Carlton Johnson resigns from Mosaic ImmunoEngineering board, effective July 23, 2024

Carlton Johnson notified the Board of his resignation effective immediately on July 23, 2024.
May 31, 2024, 7:59 PM ET leadership materiality 0.55 negative item 5.02 item 9.01 ◈ executive_change

Mosaic ImmunoEngineering CFO Paul Lytle moves to part-time, pay cut to $1,600/month

CFO Paul Lytle reduced to part-time effective June 1, 2024, max 8 hours/month, monthly rate $1,600.
May 21, 2024, 7:59 PM ET other material materiality 0.50 neutral item 4.01 item 9.01

Mosaic ImmunoEngineering changes auditor; KMJ resigns, Rose Snyder & Jacobs appointed

KMJ Corbin & Company resigned on May 21, 2024, after its partners joined Crowe LLP.
April 29, 2024, 7:59 PM ET M&A materiality 0.75 positive item 7.01 item 8.01 item 9.01

Mosaic to acquire Oncotelic's clinical necroptosis cancer assets for up to $30M in stock

Binding term sheet signed April 26, 2024; acquisition includes VDA necroptosis therapies and AI platform.
April 19, 2024, 7:59 PM ET leadership materiality 0.30 negative item 5.02 ◈ executive_change

Mosaic ImmunoEngineering announces passing of director Gloria Felcyn

Director Gloria Felcyn died on April 17, 2024.
March 28, 2024, 7:59 PM ET other material materiality 0.85 negative item 1.01 item 1.02 ◈ Material Agreements

CWRU terminates Mosaic's CPMV license for lead candidate MIE-101 over ~$407K unpaid IP fees

Effective March 22, 2024, CWRU terminated the exclusive worldwide license agreement due to financial default.

Executive changes

Departed

Carlton Johnson

Director

CPMV · Mosaic ImmunoEngineering Inc.

Effective: 2024-07-23
Filed: July 25, 2024, 7:59 PM ET

On July 23, 2024, Mr. Carlton Johnson notified the Board of Directors (the “Board”) of Mosaic ImmunoEngineering, Inc. (the “Company”) of his resignation from the Board effective immediately.

Role change

Paul Lytle

EVP, Chief Financial Officer

CPMV · Mosaic ImmunoEngineering Inc.

Effective: 2024-06-01
Filed: May 31, 2024, 7:59 PM ET

Mr. Paul Lytle, EVP, Chief Financial Officer of the Company, agreed to amend Mr. Lytle’s employment terms from full time status to part time status, not to exceed eight (8) hours per month effective June 1, 2024

Departed

Gloria Felcyn

Director

CPMV · Mosaic ImmunoEngineering Inc.

Effective: 2024-04-17
Filed: April 19, 2024, 7:59 PM ET

Mosaic ImmunoEngineering, Inc. (the “Company”) is deeply saddened to announce that director Ms. Gloria Felcyn passed away on April 17, 2024.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.50 · Most common event leadership

1 positive 3 negative 3 neutral

source · CPMV on sec.gov